Regeneron reports another manufacturing-related rejection for Eylea HD, but says help is on the way
The FDA has issued another complete response letter to Regeneron over its high-dose Eylea due to unresolved issues at a Novo Nordisk manufacturing plant. The company, however, is making progress in lining